Clinical Trial Update: Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease [Phase 4]

View source ↗

Summary

An ongoing Phase 4 study evaluating dual-targeted therapy with upadacitinib plus ustekinumab versus intensified ustekinumab in Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Crohn Disease | Phase 4 | Status: RECRUITING